

CADTH DRUG REIMBURSEMENT REVIEW

Pharmacoeconomic Report

GILTERITINIB (XOSPATA)

(Astellas Pharma Inc)

Indication: For the treatment of adult patients who have relapsed or refractory acute myeloid leukemia with a FMS-like tyrosine kinase 3 mutation.

Version: Final

Publication Date: May 20, 2020

Report Length: 18 Pages

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Table of Contents

| | |
|---|----|
| List of Tables..... | 4 |
| Abbreviations | 5 |
| Executive Summary | 6 |
| Conclusions | 9 |
| Stakeholder Input Relevant to the Economic Review..... | 10 |
| Economic Review | 11 |
| Appendix 1: Cost Comparison Table..... | 12 |
| Appendix 2: Submission Quality | 13 |
| Appendix 3: Detailed Information on the Submitted Economic Evaluation..... | 14 |
| Appendix 4: CADTH Detailed Reanalyses and Sensitivity Analyses of the Economic Evaluation | 15 |
| Appendix 5: Detailed Information on the Submitted BIA..... | 16 |

List of Tables

| | |
|--|---|
| Table 1: Submitted for Review..... | 6 |
| Table 2: Summary of Economic Evaluation..... | 7 |

Abbreviations

| | |
|----------|---|
| AE | adverse event |
| AIC | Akaike Information Criteria |
| AML | acute myeloid leukemia |
| BIA | budget impact analysis |
| BIC | Bayesian Information Criteria |
| BSA | body surface area |
| BSC | best supportive care |
| CAD | Canadian Dollars |
| CGP | clinical guidance panel |
| EQ-5D | European Quality of Life Five Dimensions |
| FLAG-IDA | Fludarabine + cytarabine + granulocyte colony-stimulating factor + idarubicin |
| FLT3 | FMS-like tyrosine kinase 3 |
| ICER | incremental cost-effectiveness ratio |
| HR | hazard ratio |
| HSCT | hematopoietic stem cell transplantation |
| KM | Kaplan-Meier |
| LDAC | low-dose cytarabine |
| LY | life year |
| MEC | mitoxantrone + etoposide + cytarabine |
| OS | overall survival |
| pCODR | CADTH pan-Canadian Oncology Drug Review |
| R/R | relapsed or refractory |
| SMR | Standardized mortality ratio |
| QALY | quality-adjusted life year |
| WTP | willingness-to-pay |

Executive Summary

The executive summary is comprised of two tables (Table 1: Background; Table 2: Economic Evaluation) and a conclusion.

Table 1: Submitted for Review

| Item | Description |
|-------------------------------|---|
| Drug product | Gilteritinib (Xospata), 40 mg tablet. |
| Submitted price | Gilteritinib, 40 mg tablet: \$325.00 |
| Indication | For the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation. A validated test is required to confirm the FLT3 mutation status of AML. |
| Health Canada approval status | NOC |
| Health Canada review pathway | Priority review |
| NOC date | Dec 23, 2019 |
| Reimbursement request | As per indication |
| Sponsor | Astellas Pharma Canada, Inc. |
| Submission history | Previously reviewed: No |

NOC = Notice of Compliance; AML = acute myeloid leukemia; FLT3 = FMS-like tyrosine kinase 3

Table 2: Summary of Economic Evaluation

| Component | Description |
|--|---|
| Type of economic evaluation | Cost-utility analysis. Decision-tree followed by partitioned survival models. |
| Target population | Adult patients with relapsed or refractory acute myeloid leukemia with an FMS-like tyrosine kinase 3 mutation (aligned with reimbursement request). |
| Treatment | Gilteritinib |
| Comparator | Base case: Salvage chemotherapy (azacitidine, FLAG-IDA, MEC, and LDAC) Scenario analyses: Best supportive care (BSC) and individual regimens (azacytidine only, FLAG-IDA only, MEC only, LDAC only) |
| Perspective | Canadian publicly funded health care payer |
| Outcomes | QALYs, LYs |
| Time horizon | Lifetime (41 years) |
| Key data source | ADMIRAL trial reporting overall survival and event-free survival without hematopoietic stem cell transplantation (HSCT). Medical literature reporting overall survival and event-free survival with HSCT. |
| Submitted results for base case | ICER = \$114,800 per QALY (1.554 incremental QALYs; \$178,423 incremental costs) |
| Key limitations | <ul style="list-style-type: none"> The sponsor used a mixture of salvage therapy regimens to represent salvage chemotherapy in the base case, however the proportion of patients receiving each individual salvage regimen were based in the ADMIRAL trial and were not reflective of the clinical practice in Canada. Individual salvage regimen comparators were considered in scenario analysis, based on the inappropriate assumption that treatment efficacy of each individual regimen was the same as the salvage chemotherapy arm observed in the ADMIRAL trial. BSC was excluded from the base case analysis even though it was a relevant comparator, however it was included in a scenario analysis. The sponsor assumed that long-term survival was associated with mortality rates twice as high as that of the general population based on clinical expert opinion for a different product for FLT3-mutated AML that underwent reimbursement review in another country. Values from the literature suggest a 4 to 9-fold increase in mortality (compared to the general population). This suggests an overestimation in OS in the sponsor's analysis. Furthermore, the sponsor assumed that patients on maintenance gilteritinib post-HSCT would receive OS benefits, which was based on immature data with short follow-up. This assumption was deemed to be unrealistic and leads to further overestimation of OS favouring gilteritinib. Adjustment of treatment costs according to dose intensity underestimated costs of oral treatments, possibly favouring gilteritinib. Only grade 3 and 4 AEs that affected ≥5% of the patients were included in the sponsor's analyses. Some AEs considered clinically meaningful (such as cardiac toxicities, fatigue and vomiting) according to clinical experts and patient groups consulted by CADTH were excluded, possibly overestimating the benefits to gilteritinib. |
| CADTH reanalysis results | <ul style="list-style-type: none"> CADTH reanalyses included: adding BSC as comparator, alternative salvage chemotherapy treatment distributions based on clinical expert feedback, alternative standardized mortality ratio (SMR) for long-term survivors based on the literature, exclusion of gilteritinib OS benefit post-HSCT, and revised dose intensity for oral treatments. BSC would be cost-effective if a decision-maker is willing to pay less than \$98,720 for a QALY. Salvage chemotherapy is the optimal therapy if the willingness-to-pay threshold is at least \$98,720 but less than \$168,451 per QALY gained; and gilteritinib is the optimal therapy at a willingness-to-pay threshold of at least \$168,451. A price reduction of approximately 40% and 90% would be required for gilteritinib to achieve an ICER of \$100,000 and \$50,000 per QALY, respectively. |

BSC = best supportive care; ICER = incremental cost-effectiveness ratio; FLAG-IDA = Fludarabine + cytarabine + granulocyte colony stimulating factor + idarubicin; HSCT = hematopoietic stem cell transplantation; LDAC = Low-dose cytarabine; LY = life-year; MEC = Mitoxantrone + etoposide + cytarabine; QALY= quality-adjusted life-year.

Conclusions

CADTH undertook reanalyses to address some of the identified limitations, i.e., adding BSC as comparator, alternative salvage chemotherapy treatment distributions based on clinical expert feedback, alternative SMR for long-term survivors based on the literature, exclusion of post-HSCT gilteritinib benefit, and revised dose intensity for oral treatments.

Following CADTH reanalysis, BSC had the lowest cost and fewest QALYs followed by salvage chemotherapy and by gilteritinib. At a willingness-to-pay threshold of less than \$98,720 per QALY BSC is the optimal therapy. Salvage chemotherapy is the optimal therapy if the willingness-to-pay threshold is at least \$98,720 but less than \$168,451 per QALY gained; and gilteritinib is the optimal therapy at a willingness-to-pay threshold of at least \$168,451. A price reduction of approximately 40% and 90% for gilteritinib would be required to bring the ICER to \$100,000, and \$50,000 per QALY, respectively.

Some identified limitations could not be addressed by CADTH (e.g., missing relevant comparators such as midostaurin, the use of a fixed timepoint after which a proportion of patients undergo HSCT, the impact of different sequences of subsequent treatment, and impact of grade 1 and 2 AEs relevant to patients). Furthermore, the comparative-effectiveness of gilteritinib versus each individual salvage regimen (i.e., FLAG-IDA, MEC, azacitadine, LDAC) is unknown due to the lack of clinical efficacy data.

Based on the sponsor's submitted budget impact analysis, the total incremental cost is estimated to be [REDACTED] over the first 3 years. CADTH reanalysis suggests that the budget impact of introducing gilteritinib to the market was underestimated in the sponsor's results and estimated to be \$47,750,562 over the first 3 years in CADTH reanalysis. *(Non-disclosable information was used in this pCODR Guidance Report and the sponsor requested this economic information not be disclosed pursuant to the pCODR Disclosure of Information Guidelines. This information will remain redacted until notification by the sponsor that it can be publicly disclosed.)*

Stakeholder Input Relevant to the Economic Review

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Economic Review

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 1: Cost Comparison Table

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 2: Submission Quality

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 3: Detailed Information on the Submitted Economic Evaluation

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 4: CADTH Detailed Reanalyses and Sensitivity Analyses of the Economic Evaluation

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

Appendix 5: Detailed Information on the Submitted BIA

This section outlines the technical details of the pCODR Economic Guidance Panel's evaluation of the economic evidence that is summarized in the executive summary. In accordance with the *Disclosure of Information Guidelines for the CADTH Pan-Canadian Oncology Drug Review*, this section is not eligible for disclosure. It was provided to the pCODR Expert Review Committee (pERC) for their deliberations and the participating drug programs for their information.

References

1. Pharmacoeconomic evaluation. In: pan-Canadian Oncology Drug Review sponsor submission: Xospata® (gilteritinib), 40 mg tablets. Markham (ON): Astellas Pharma Canada; 2019.
2. Astellas Pharma. NCT03182244: A study of ASP2215 versus salvage chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation. *ClinicalTrials.gov*. Bethesda (MD): U.S. National Library of Medicine; 2017: <https://clinicaltrials.gov/show/NCT03182244>. Accessed 2019 Nov 7.
3. PrXospata™ (gilteritinib tablets) [product monograph]. Markham (ON): Astellas Pharma Canada; 2019 Dec 23: https://www.astellas.com/ca/system/files/xospata_pm_23dec2019.pdf. Accessed 2020 Mar 30.
4. Midostaurin for untreated acute myeloid leukaemia. *Technology appraisal guidance [TA523]*. London (UK): National Institute for Health and Care Excellence; 2018 <https://www.nice.org.uk/guidance/ta523>. Accessed 2019 Dec 19.
5. Protocol for phase 3 study of ASP2215: A phase 3 open-label, multicenter, randomized study of ASP2215 versus salvage chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation; 2017. In: pan-Canadian Oncology Drug Review sponsor submission: Xospata® (gilteritinib), 40 mg tablets. Markham (ON): Astellas Pharma Canada; 2019.
6. Sarkozy C, Gardin C, Gachard N, et al. Outcome of older patients with acute myeloid leukemia in first relapse. *Am J Hematol*. 2013;88(9):758-764.
7. Evers G, Beelen DW, Braess J, et al. Outcome of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT) beyond first complete remission (CR1) [abstract]. *Blood*. 2018;132(Suppl 1):4649.
8. Ustun C, Giannotti F, Zhang MJ, et al. Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis. *Leukemia*. 2017;31(6):1408-1414.
9. Bejanyan N, Weisdorf DJ, Logan BR, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. *Biol Blood Marrow Transplant*. 2015;21(3):454-459.
10. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. *Haematologica*. 2012;97(12):1916-1924.
11. Othus M, Mukherjee S, Sekeres M, et al. Prediction of CR following a second course of '7+ 3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. *Leukemia*. 2016;30(8):1779.
12. Joshi N, Hensen M, Patel S, Xu W, Lasch K, Stolk E. Health state utilities for acute myeloid leukaemia: a time trade-off study. *Pharmacoeconomics*. 2019;37(1):85-92.
13. Ontario drug benefit formulary/comparative drug index. Toronto (ON): Ontario Ministry of Health Long-Term Care; 2019: <https://www.formulary.health.gov.on.ca/formulary/>. Accessed 2019 Dec 19.
14. DeltaPA. [Ottawa (ON)]: IQVIA; 2019: <https://www.iqvia.com/>. Accessed 2019 Dec 19.
15. Ontario Case Costing Initiative (OCCI). Toronto (ON): Ontario Health and Long-Term Care; 2018: <https://www.ontario.ca/data/ontario-case-costing-initiative-occi>. Accessed 2019 Dec 19.
16. Patient cost estimator. Ottawa (ON): Canadian Institute for Health Information; 2019: <https://www.cihi.ca/en/patient-cost-estimator>. Accessed 2019 Dec 19.
17. Schedule of benefits: physician services under the Health Insurance Act. Toronto (ON): Ontario Ministry of Health and Long-Term Care; 2015: http://www.health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob_master20181115.pdf. Accessed 2019 Dec 19.
18. Midostaurin (Rydapt) for acute myeloid leukemia. *pan-Canadian Oncology Drug Review initial economic guidance report* Ottawa (ON): CADTH; 2017: https://www.cadth.ca/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_fn_egr.pdf. Accessed 2019 Dec 19.
19. Martin PJ, Counts GW, Jr., Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. *J Clin Oncol*. 2010;28(6):1011-1016.
20. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib prolongs survival in patients with FLT3-mutated relapsed/refractory AML: phase 3 ADMIRAL trial results [abstract]. *Swiss Med Wkly*. 2019;149(Suppl 237):3S-4S.
21. Alberta population norms for EQ-5D-5L. Edmonton (AB): Alberta PROMS and EQ-5D Research and Support Unit (APERSU); 2018: https://apersu.ca/wp-content/uploads/2018/10/Alberta-Norms-Report_APERSU.pdf. Accessed 2020 Jan 3.
22. Guertin JR, Feeny D, Tarride JE. Age- and sex-specific Canadian utility norms, based on the 2013-2014 Canadian Community Health Survey. *CMAJ*. 2018;190(6):E155-e161.
23. Clinical trials using crenolanib besylate. Bethesda (MD): National Cancer Institute: <https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/crenolanib-besylate>. Accessed 2019 Dec 19.

24. EUCTR2016-001643-39: A phase 3 multicenter, randomized, double-blind, placebo-controlled trial of the FLT3 inhibitor gilteritinib (ASP2215) administered as maintenance therapy following induction/consolidation therapy for subjects with FLT3/ITD AML in first complete remission. *EU Clinical Trials Register*. Amsterdam (NL): European Medicines Agency; 2016: <https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001643-39/PT>. Accessed 2019 Nov 7.
25. Swinburn P, Lloyd A, Nathan P, Choueiri TK, Cella D, Neary MP. Elicitation of health state utilities in metastatic renal cell carcinoma. *Curr Med Res Opin*. 2010;26(5):1091-1096.
26. Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. *Br J Cancer*. 2006;95(6):683.
27. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. *Health Qual Life Outcomes*. 2008;6(1):84.
28. Blood cancer in Canada: facts & stats 2016. Toronto (ON): Leukemia & Lymphoma Society of Canada; 2017: https://www.llscanada.org/sites/default/files/National/CANADA/Pdf/InfoBooklets/Blood_Cancer_in_Canada_Facts_%26_Stats_2016.pdf. Accessed 2019 Dec 19.
29. Xospata market overview & key assumptions. In: pan-Canadian Oncology Drug Review sponsor submission: Xospata® (gilteritinib), 40 mg tablets. Markham (ON): Astellas Pharma Canada; 2019.
30. Enasidenib (Idhifa) for acute myeloid leukemia. *pan-Canadian Oncology Drug Review initial economic guidance report*. Ottawa (ON): CADTH; 2019: https://cadth.ca/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_inEGR_NOREDACT-ABBREV_Post_29Aug2019_final.pdf. Accessed 2019 Dec 19.
31. Budget impact analysis guidelines. Ottawa (ON): Patented Medicine Prices Review Board; 2007: <http://www.pmprb-cepmb.gc.ca/cmfiles/bia-may0738lvv-5282007-5906.pdf>. Accessed 2019 Dec 1.